BioSpace News Archive

Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

Researchers with Pfizer and IBM developed an artificial intelligence (AI) model that they claim can predict eventual onset of Alzheimer’s disease with 71% accuracy based on a language sample. They published the research today in The Lancet eClinicalMedicine.

Two Phase III studies of lumasiran showed a significant reduction in urinary oxalate excretion in patients of all ages with PH1. Know more about it here.

Shares of Gilead Sciences are jumping in aftermarket trading following full approval for Veklury (remdesivir) as a treatment for COVID-19. The approval marks the first drug approved by the U.S. Food and Drug Administration as a treatment for the novel coronavirus.

Sequana Medical NV, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces positive interim results from the first five patients enrolled in the RED DESERT study, evaluating repeated dose treatment of alfapump DSR in diuretic-resistant heart failure patients.

Atea Pharmaceuticals, Inc. announces that the company has entered into an agreement with Roche for the exclusive rights to research, develop and distribute AT-527 as an oral antiviral treatment for COVID-19 in territories outside of the United States.

Ipsen, a global specialty-driven biopharmaceutical group, announced sales for the third quarter of 2020.

Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced the pricing of its public offering of 4,687,500 shares of its common stock at a public offering price of $40.00 per share.

BioInvent International AB announces that it will receive a €2 million milestone payment under its collaboration with Daiichi Sankyo related to the initiation of a global Phase I clinical trial with an anti-glycoprotein A repetitions predominant directed antibody.

Alligator Bioscience announced the decision to focus its resources on the two proprietary candidate drugs, ATOR-1017 and mitazalimab.